This clinical practice guideline is a focused update on management of Clostridioides difficile
infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for …

The present work aims to examine the worrying problem of antibiotic resistance and the
emergence of multidrug-resistant bacterial strains, which have now become really common …

Background Clostridioides difficile is a Gram-positive anaerobic bacterium, which causes
Clostridioides difficile infection (CDI). It has been recognised as a leading cause of …

Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI)
are limited, with high recurrence rates associated with the current standard of care. Herein …

Background Bezlotoxumab is a human monoclonal antibody against Clostridium difficile
toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk …

In the last three decades, Clostridium difficile infection (CDI) has increased in incidence and
severity in many countries worldwide. The increase in CDI incidence has been particularly …

Abstract Background Despite advancements, recurrent Clostridium difficile infections (CDI)
remain an urgent public health threat with insufficient response rates to currently approved …

C. difficile infection (CDI) is a worldwide healthcare problem with~ 30% of cases failing
primary therapy, placing a burden on healthcare systems and increasing patient morbidity …

Clostridium (reclassified as “Clostridioides”) difficile infection (CDI) is a healthcare-
associated infection and significant source of potentially preventable morbidity, recurrence …

Importance RecurrentClostridioides difficileinfection (CDI) is a debilitating disease leading to
poor health-related quality of life (HRQOL), loss of productivity, anxiety, and depression. The …